S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
NYSEARCA:XBI

SPDR S&P Biotech ETF (XBI) Price, Holdings, & News

$84.65
-0.96 (-1.12%)
(As of 04/17/2024 ET)
Today's Range
$84.55
$86.30
50-Day Range
$84.65
$102.93
52-Week Range
$63.80
$103.52
Volume
11.84 million shs
Average Volume
11.72 million shs
Market Capitalization
$6.58 billion
Assets Under Management
$6.41 billion
Dividend Yield
0.02%
Net Expense Ratio
0.35%
XBI stock logo

About SPDR S&P Biotech ETF (NYSEARCA:XBI)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

XBI Stock Price History

XBI ETF News Headlines

2 Top Biotech Buyout Candidates
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
3 Biotech Stocks to Buy on the Dip: March 2024
3 Biotech ETFs Overdue for a Bounce
Heard on the Street Recap: Zooming Up
Spdr S&P Biotech Etf
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
XBI ETF Stock Price History
See More Headlines
Receive XBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
SSgA
Fund Name
SPDR S&P Biotech ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:XBI
Inception Date
1/31/2006
Fund Manager
Michael Feehily, Karl Schneider, Raymond Donofrio

Fund Focus

Asset Class
Equity
Benchmark
S&P Biotech Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
139

Fund Statistics

Assets Under Management
$6.41 billion
Average Daily Volume
$11.20 million
Discount/Premium
0.04%

Administrator, Advisor and Custodian

Administrator
SSgA Funds Management, Inc.
Advisor
SSgA Funds Management, Inc.
Custodian
State Street Bank and Trust Company
Distributor
State Street Global Advisors Funds Distributors, LLC
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
Optionable
Options Volume
96,050
Put Options
59,124
Call Options
36,926
Short Interest
53,110,000 shs

Miscellaneous

Beta
1.08
Creation Unit
50,000
Creation Fee
$250.00
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

SPDR S&P Biotech ETF Expenses

TypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.35%0.56%0.54%0.50%0.51%
Other Expenses0.00%0.40%0.54%0.64%0.58%
Total Expense0.35%0.72%0.70%0.74%0.70%
Fee Waiver0.00%-0.53%-0.55%-0.68%-0.57%
Net Expense0.35%0.60%0.60%0.58%0.58%

SPDR S&P Biotech ETF (XBI) Holdings & Exposure

Key Executives

  • James E. Ross (Age 52)
    President, Trustee
  • Peter A. Ambrosini (Age 69)
    Chief Compliance Officer
  • Michael P. Riley (Age 44)
    Vice President
  • Gary L. French (Age 64)
    Treasurer
  • John W. Clark (Age 46)
    Assistant Treasurer
  • Matthew W. Flaherty (Age 42)
    Assistant Treasurer
  • Chad C. Hallett (Age 47)
    Assistant Treasurer of Street tracks series trust
  • Mary Moran Zeven (Age 52)
    Secretary
  • Scott M. Zoltowski (Age 44)
    Assistant Secretary
  • Dave Kelly
    Independent Trustee

XBI ETF - Frequently Asked Questions

How have XBI shares performed in 2024?

SPDR S&P Biotech ETF's stock was trading at $89.29 on January 1st, 2024. Since then, XBI shares have decreased by 5.2% and is now trading at $84.65.
View the best growth stocks for 2024 here
.

What does XBI invest in?

SPDR S&P Biotech ETF is a equity fund issued by SSgA. XBI focuses on health care investments and follows the S&P Biotech Index. The fund's investments total to approximately $6.41 billion assets under management.

What is the management fee for SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XBI is 0.35%.

What other stocks do shareholders of SPDR S&P Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS), Micron Technology (MU), Cisco Systems (CSCO), AbbVie (ABBV) and Netflix (NFLX).

Who are SPDR S&P Biotech ETF's major shareholders?

SPDR S&P Biotech ETF's stock is owned by many different institutional and retail investors. Top institutional investors include Alaska Permanent Fund Corp (1.13%), Wealth Enhancement Advisory Services LLC (0.15%), Edge Wealth Management LLC (0.14%), Parkside Investments LLC (0.12%), CMH Wealth Management LLC (0.09%) and Marotta Asset Management (0.08%).

How do I buy shares of SPDR S&P Biotech ETF?

Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEARCA:XBI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners